These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 22173446)
1. Tyrosine kinase inhibitors in hematological malignancies. Kosior K; Lewandowska-Grygiel M; Giannopoulos K Postepy Hig Med Dosw (Online); 2011 Dec; 65():819-28. PubMed ID: 22173446 [TBL] [Abstract][Full Text] [Related]
2. Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia. Klyuchnikov E; Schafhausen P; Kröger N; Brummendorf TH; Osanmaz O; Asenova S; Zabelina T; Ocheni S; Ayuk F; Zander AR; Bacher U Acta Haematol; 2009; 122(1):6-10. PubMed ID: 19602874 [No Abstract] [Full Text] [Related]
3. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254 [No Abstract] [Full Text] [Related]
4. Development of novel tyrosine kinase inhibitors for treatment of imatinib-resistant CML patients. Kimura S Rinsho Ketsueki; 2009 Jul; 50(7):547-55. PubMed ID: 19638722 [No Abstract] [Full Text] [Related]
5. New and established tyrosine kinase inhibitors for chronic myeloid leukemia. Thienelt CD; Green K; Bowles DW Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801 [TBL] [Abstract][Full Text] [Related]
6. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Irvine E; Williams C Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655 [TBL] [Abstract][Full Text] [Related]
7. Novel agents in CML therapy: tyrosine kinase inhibitors and beyond. Melo JV; Chuah C Hematology Am Soc Hematol Educ Program; 2008; ():427-35. PubMed ID: 19074121 [TBL] [Abstract][Full Text] [Related]
10. As leukemia options grow, drugs jockey to be first-line therapies. Dolgin E Nat Med; 2013 Jan; 19(1):7. PubMed ID: 23295994 [No Abstract] [Full Text] [Related]
11. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Steinberg M Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072 [TBL] [Abstract][Full Text] [Related]